How I Got My Start in Value Investing


My Value Investing Roots

Three Geniuses and Me!

Nu Skin Enterprises (NUS): Quality, Value and Growth


If you’ve been reading my Cabot Wealth Advisory columns for a while, you know that I’m a strong advocate of value investing as a safe way to profit in the stock market—in fact, it’s been a central force in my investing life since I’ve had any money to invest!

Like many college students, I was inspired to enter my particular field by an extraordinary professor, but the story actually begins much earlier than that.

Back in 1946, Dr. Wilson Payne and Benjamin Graham held meetings at Babson College to find a way to calculate the true fundamental value of a company. Dr. Payne was the Dean of the Investment Department at Babson College (known back then as Babson Institute) and Benjamin Graham was professor of Advanced Security Analysis at Columbia University and investment advisor with the Graham-Newman Corporation. The two collaborated to devise formulas that would estimate a fair value range for stocks based on Mr. Graham’s guidelines.

Many years later, I attended Babson, 15 miles west of Boston, and majored in Finance and Investments. I had the good fortune to take several courses taught by Dr. Payne, who made a lasting impression on me. Dr. Payne, a genius in math, made learning fundamental securities analysis painless. His teachings were based upon Benjamin Graham’s analyses.

After graduating from Babson, I worked for Paine, Webber in Boston for a few years and, after a stint in the Army, I was hired as Director of Research at Econometrics Research and Management in Boston. I was given the task of developing a computerized research system to analyze and evaluate stocks. I called upon my old friend and college professor, who was more than willing to lend assistance for free!

In 1969, Dr. Wilson Payne and I teamed up to develop computerized models using the formulas which he and Ben Graham devised to estimate the true fundamental value for companies 23 years earlier. We hired Dr. Richard Fey, a math professor at Boston University, and two computer programmers. And there I was, a newbie in the very sophisticated world of investments, standing among giants!

We developed a reliable system to estimate Maximum Buy Prices to indicate when to buy a stock, and Minimum Sell Prices to estimate when to sell a stock. In addition, we added Benjamin Graham’s guidelines for standards of quality, value and earnings growth to quantify each company’s attributes for comparison purposes.

I left Econometrics a few years later, after buying the exclusive rights to use the software programs that my team worked so hard to develop. I still own the rights and now use my computers to perform all of the calculations we developed decades ago. I am happy to report that the analyses we developed, based on Benjamin Graham’s teachings during the 1930s and 1940s, still work very well!

If This Week's Trades Don't Hand You At Least 30% Profits in 60 Days--You Won't Pay a Dime

Cabot Top Ten Trader's results have left our readers smiling all the way to the bank, with annualized profits of up to 50% on each of our trades--coming in as little as 30 days--even with the losers thrown in. All thanks to breakout winners like these...

  • Continental Resources 122%
  • Encore Aqua 101%
  • Cleveland Cliffs 93%
  • DryShips 95%
  • McMorRan Expl 91%
  • M&F Worldwide 78%

Don't wait until after the next economic numbers come out or the big profits will have passed you by. If you're serious about grabbing your share of profits from these quick trades, now is the time to join us...

For more, click here for details.

My wife and I have further adapted my old computer programs to fit today’s modern computer operating systems. She’s an expert programmer. Our computers crank out two million calculations at the beginning of every month to create dependable ratings and forecasts.

Benjamin Graham emphasized investing in high quality companies. In his mind, all else is a gamble not an investment. For this reason, I include only 1,000 high-quality companies in my value stock database.

In addition to looking for high quality ratings, I also seek companies with high value and growth ratings. I can easily find undervalued companies by comparing a company’s current price to my Graham-generated Maximum Buy Price target.

Finally, I find companies with high growth ratings. These ratings are based on past, current and forecast growth rates for sales, earnings, dividends, cash flow, and book value.

During the past 17 years, I have recommended high-quality undervalued companies with steady growth every month in the Cabot Benjamin Graham Value Letter and its predecessor. My recommendations have increased 640% compared to an advance of 134% for the Standard & Poor’s 500 Index during the same period through September 30, 2012.

More recently, my recommendations have increased 27% since the beginning of this year which is far better than the comparable gain of 15% for the S&P 500 or the performance of mutual funds and hedge funds. High-quality stocks that are undervalued have consistently outperformed the stock market indexes in both advancing and declining markets. Investing in quality stocks at bargain prices makes sense in any stock market environment.

Want an Annual Return of 15% plus generous dividend yields?

The objective of my ultra-low-risk investing system promises to help you find the
strongest dividend stocks, no matter the market environment. My system also finds
faster growing companies before they initiate dividends.

You'll be able to take advantage of margins of safety and Maximum Buy and
Minimum Sell Prices designed to boost your portfolio's gains while also protecting
you from the whipsaw action of dips and corrections.

Just look at these gains which my subscribers earned in 2013:

  • Advance Auto Parts UP 81%
  • Celgene UP 105%
  • eBay UP 89%
  • LKQ Corp. UP 123%
  • Reinsurance Group UP 70%
  • TJX Companies UP 133%

My system is simple: buy high-quality stocks when they are undervalued, and
sell when the stocks become overvalued. Buy low and sell high – it doesn't get any simpler!

Click here for more Roy Ward picks!

After scanning my 1,000 stock database to find a stock that fits well within Benjamin Graham’s parameters for quality, value and growth, I find that Nu Skin Enterprises has all the attributes needed to shine during the next one to two years.

Nu Skin Enterprises (NUS: 41.92) Max Buy Price = 40.34; Min Sell Price = 65.61 Develops and distributes personal care products and nutritional supplements under the Nu Skin and Pharmanex brand names. Based in Provo Utah, NUS derives a whopping 86% of sales from outside North and South America. Europe contributes less than 10% of sales.

An analysis of Nu Skin’s fundamentals reveals how attractive the company is. Using the analyses developed by Benjamin Graham and Dr. Wilson Payne, Nu Skin scores high in almost all rating categories.

I double-check my ratings and estimates with the leading research services to make sure my underlying data is accurate. Nu Skin’s high quality rating in the Ben Graham system is derived from the company’s balance sheet, which contains low debt and lots of cash ($6.20 per share) and from Nu Skin’s record of steady sales, earnings, and dividend growth during the past decade. My high quality rating is supported by Standard & Poor’s quality rating of A-, S&P’s third highest ranking.

Nu Skin is undervalued. Its stock price is currently just above my Maximum Buy Price of 40.34 and below Standard & Poor’s discounted cash flow value of 51.40.

Nu Skin’s high growth rating is bolstered by the company’s steady 10% sales and earnings growth during the past decade. The future looks even brighter: I project EPS growth of 15.7% annually during the next five years. My favorable growth rating is reinforced by IBD’s (Investor Business Daily’s) Growth Rating of 99, IBD’s highest score.

NUS’s stock price performance has been disappointing during the past six months. Worries about the company’s new product development in China and Japan led to a 20 point drop in NUS’s stock price five months ago. However, Nu Skin successfully launched its suite of AgeLOC products in China in April, which boosted sales significantly in the second quarter. Apparently, the slowdown in Nu Skin sales in China will not materialize. Therefore, I believe the current stock weakness presents an excellent buying opportunity.

Sales increased 23% and EPS (earnings per share) soared 56% during the past 12 months ended 6/30/12. I expect sales to increase 12% and EPS to rise 14% during the next 12 months. At 12.8 times latest EPS, NUS shares are a bargain. The dividend yield of 2.0% and Low Risk rating create an excellent investment opportunity. I advise buying NUS at or below 40.34 which is my Maximum Buy Price. Sell when NUS’s stock price reaches my Minimum Sell Price of 65.61 within the next one to two years.

Until next time, be kind and friendly to everyone you meet.


J.Royden Ward
Editor of Benjamin Graham Value Letter

Editor’s Note: You can read more Benjamin Graham and receive continuing coverage of Nu Skin Enterprises in the Cabot Benjamin Graham Value Letter. There you’ll not only find buy and sell advice for Nu Skin, you'll get 20 other excellent value stock recommendations from J. Royden Ward each and every month. Roy applies the strategy of the father of value investing, Benjamin Graham, to find the market’s best undervalued stocks. And he will tell you exactly when to sell. Don’t miss out on his next recommendations ... click here now to get started today!

Stock Picks

Ross Stores

McKesson (MCK) distributes ethical and proprietary drugs, surgical supplies and health and beauty products throughout North America to the healthcare industry. The company also provides technical consulting services to biotech and pharmaceutical manufacturers.

Carnival Cruise Lines

Having just returned from vacation, Tim Lutts is thinking of the millions of baby-boomers who are spending more and more money on leisure travel, particularly on cruises, an industry that is dominated by a few big players.

China Biologic Products

Paul Goodwin advises putting this stock on your watch list.

Cabot Wealth Advisory

Managing Your Stock Portfolio to the Market's Tune

By Michael Cintolo on July 30, 2015

In today’s Wealth Advisory, I’m doing something I’ve never done before—reprinting an entire piece I wrote in Cabot Growth Investor last Wednesday. It doesn’t involve any specific stock advice (that is and always will be for subscribers only), but it details the wild divergences in the market (which are now getting lots of press—even the Wall Street Journal had a big write-up on it Monday), what it means, and how I’m advising people to handle it—I think it’s very timely.Read More >

Do Your Stocks Have Borrowing Trouble?

By Nancy Zambell on July 28, 2015

Hostess is making news today as it is issuing $1.23 million in term loans—most of which will go toward paying $905 million in a special dividend to its private shareholders—which I may add, is also more than two times what the buyers paid for this tasty snack business, and triples the company’s debt. According to Bloomberg, these types of deals grew to nearly $16 billion in the second quarter, the highest level in the past 12 months. I’m not making a judgment for or against this action. I just want to make a point that this debt, or leverage recapitalization—spurred by low interest rates—is increasingly becoming a method in which private equity holders get their money back—without selling the business. But it does burden the company with additional debt, which isn’t going to fund company expansion or operations.Read More >

Sell Apple

By Timothy Lutts on July 27, 2015

Today, I’m writing on a MacBook Pro. This morning I did my morning crossword puzzle on my iPad. All day long, my iPhone is by my side. My home Wi-Fi comes from Apple AirPorts. And some nights, I stream entertainment through my Apple TV. In short, I love Apple products, and I expect to continue using them for many more years. But one of the most important market truisms is this: “The company is not the stock.”Read More >